1. Home
  2. DPRO vs CHRS Comparison

DPRO vs CHRS Comparison

Compare DPRO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Draganfly Inc.

DPRO

Draganfly Inc.

HOLD

Current Price

$6.48

Market Cap

188.8M

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.36

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DPRO
CHRS
Founded
1998
2010
Country
Canada
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
188.8M
177.7M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
DPRO
CHRS
Price
$6.48
$1.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$15.00
$5.51
AVG Volume (30 Days)
1.2M
1.3M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$158.69
$73.08
Revenue Next Year
$131.85
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.78
$1.09
52 Week High
$14.37
$2.62

Technical Indicators

Market Signals
Indicator
DPRO
CHRS
Relative Strength Index (RSI) 76.83 50.32
Support Level $6.07 $1.34
Resistance Level $6.56 $1.46
Average True Range (ATR) 0.30 0.09
MACD 0.20 0.01
Stochastic Oscillator 92.95 70.00

Price Performance

Historical Comparison
DPRO
CHRS

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: